Literature DB >> 24657149

Dopamine D2 receptor desensitization by dopamine or corticotropin releasing factor in ventral tegmental area neurons is associated with increased glutamate release.

Sudarat Nimitvilai1, Melissa Herman2, Chang You1, Devinder S Arora1, Maureen A McElvain1, Marisa Roberto2, Mark S Brodie3.   

Abstract

Neurons of the ventral tegmental area (VTA) are the source of dopaminergic (DAergic) input to important brain regions related to addiction. Prolonged exposure of these VTA neurons to moderate concentrations of dopamine (DA) causes a time-dependent decrease in DA-induced inhibition, a complex desensitization called DA inhibition reversal (DIR). DIR is mediated by conventional protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of some Gq-linked receptors. Corticotropin releasing factor (CRF) acts via Gq, and can modulate glutamater neurotransmission in the VTA. In the present study, we used brain slice electrophysiology to characterize the interaction of DA, glutamate antagonists, and CRF agonists in the induction and maintenance of DIR in the VTA. Glutamate receptor antagonists blocked induction but not maintenance of DIR. Putative blockers of neurotransmitter release and store-operated calcium channels blocked and reversed DIR. CRF and the CRF agonist urocortin reversed inhibition produced by the D2 agonist quinpirole, consistent with our earlier work indicating that Gq activation reverses quinpirole-mediated inhibition. In whole cell recordings, the combination of urocortin and quinpirole, but not either agent alone, increased spontaneous excitatory postsynaptic currents (sEPSCs) in VTA neurons. Likewise, the combination of a D1-like receptor agonist and quinpirole, but not either agent alone, increased sEPSCs in VTA neurons. In summary, desensitization of D2 receptors induced by dopamine or CRF on DAergic VTA neurons is associated with increased glutamatergic signaling in the VTA.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Desensitization; Dopamine D2 receptor; Glutamate; Quinpirole; Urocortin; sEPSC

Mesh:

Substances:

Year:  2014        PMID: 24657149      PMCID: PMC4038332          DOI: 10.1016/j.neuropharm.2014.03.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  74 in total

1.  Cellular localization and distribution of dopamine D(4) receptors in the rat cerebral cortex and their relationship with the cortical dopaminergic and noradrenergic nerve terminal networks.

Authors:  A Rivera; A Peñafiel; M Megías; L F Agnati; J F López-Téllez; B Gago; A Gutiérrez; A de la Calle; K Fuxe
Journal:  Neuroscience       Date:  2008-06-17       Impact factor: 3.590

2.  Reversal of prolonged dopamine inhibition of dopaminergic neurons of the ventral tegmental area.

Authors:  Sudarat Nimitvilai; Mark S Brodie
Journal:  J Pharmacol Exp Ther       Date:  2010-02-17       Impact factor: 4.030

3.  Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety.

Authors:  Younglim Lee; Stephanie Fitz; Philip L Johnson; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

4.  Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons.

Authors:  Can Gao; Marina E Wolf
Journal:  J Neurochem       Date:  2008-07-30       Impact factor: 5.372

5.  Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition.

Authors:  Elyssa B Margolis; Jennifer M Mitchell; Junko Ishikawa; Gregory O Hjelmstad; Howard L Fields
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

6.  Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling.

Authors:  Eric Gutknecht; Ilse Van der Linden; Kristof Van Kolen; Kim F C Verhoeven; Georges Vauquelin; Frank M Dautzenberg
Journal:  Mol Pharmacol       Date:  2008-12-19       Impact factor: 4.436

7.  Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids.

Authors:  Véronique M André; Carlos Cepeda; Damian M Cummings; Emily L Jocoy; Yvette E Fisher; X William Yang; Michael S Levine
Journal:  Eur J Neurosci       Date:  2009-12-21       Impact factor: 3.386

8.  Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons.

Authors:  Hui-Ling Wang; Marisela Morales
Journal:  J Comp Neurol       Date:  2008-07-20       Impact factor: 3.215

9.  Acute and chronic dopamine receptor stimulation modulates AMPA receptor trafficking in nucleus accumbens neurons cocultured with prefrontal cortex neurons.

Authors:  Xiu Sun; Michael Milovanovic; Yun Zhao; Marina E Wolf
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

Review 10.  A ventral tegmental CRF-glutamate-dopamine interaction in addiction.

Authors:  Roy A Wise; Marisela Morales
Journal:  Brain Res       Date:  2009-10-01       Impact factor: 3.252

View more
  10 in total

1.  GIRK3 gates activation of the mesolimbic dopaminergic pathway by ethanol.

Authors:  Melissa A Herman; Harpreet Sidhu; David G Stouffer; Max Kreifeldt; David Le; Chelsea Cates-Gatto; Michaelanne B Munoz; Amanda J Roberts; Loren H Parsons; Marisa Roberto; Kevin Wickman; Paul A Slesinger; Candice Contet
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

2.  Diacylglycerol lipase disinhibits VTA dopamine neurons during chronic nicotine exposure.

Authors:  Matthew W Buczynski; Melissa A Herman; Ku-Lung Hsu; Luis A Natividad; Cristina Irimia; Ilham Y Polis; Holly Pugh; Jae Won Chang; Micah J Niphakis; Benjamin F Cravatt; Marisa Roberto; Loren H Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

3.  A role for corticotropin-releasing factor signaling in the lateral habenula and its modulation by early-life stress.

Authors:  Michael E Authement; Ludovic D Langlois; Ryan D Shepard; Caroline A Browne; Irwin Lucki; Haifa Kassis; Fereshteh S Nugent
Journal:  Sci Signal       Date:  2018-03-06       Impact factor: 8.192

Review 4.  Translating striatal activity from brain slice to whole animal neurophysiology: A guide for neuroscience research integrating diverse levels of analysis.

Authors:  Howard Casey Cromwell
Journal:  J Neurosci Res       Date:  2019-06-30       Impact factor: 4.164

Review 5.  Corticotropin-Releasing Factor (CRF) and Addictive Behaviors.

Authors:  Marisa Roberto; Samantha R Spierling; Dean Kirson; Eric P Zorrilla
Journal:  Int Rev Neurobiol       Date:  2017-08-07       Impact factor: 3.230

6.  Prefrontal and Striatal Glutamate Differently Relate to Striatal Dopamine: Potential Regulatory Mechanisms of Striatal Presynaptic Dopamine Function?

Authors:  Tobias Gleich; Lorenz Deserno; Robert Christian Lorenz; Rebecca Boehme; Anne Pankow; Ralph Buchert; Simone Kühn; Andreas Heinz; Florian Schlagenhauf; Jürgen Gallinat
Journal:  J Neurosci       Date:  2015-07-01       Impact factor: 6.167

7.  An Assessment between D1 Receptor Agonist and D2 receptor Antagonist into the Ventral Tegmental Area on Conditioned Place Preference and Locomotor Activity.

Authors:  Seyed Mostafa Ahmadian; Hojjatallah Alaei; Parisa Ghahremani
Journal:  Adv Biomed Res       Date:  2019-12-24

8.  Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Alexis Erb; Felix Gonzalez Lopera; Vlad Danila; Mihaela Tomsa
Journal:  Brain Sci       Date:  2021-03-26

Review 9.  Diversity of Dopaminergic Neural Circuits in Response to Drug Exposure.

Authors:  Barbara Juarez; Ming-Hu Han
Journal:  Neuropsychopharmacology       Date:  2016-03-03       Impact factor: 7.853

Review 10.  Ethanol actions on the ventral tegmental area: novel potential targets on reward pathway neurons.

Authors:  Chang You; Bertha Vandegrift; Mark S Brodie
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.